机构:[1]Department of General Surgery, Sun Yat-Sen Memorial Hospital, Guangzhou, China.中山大学附属第二医院[2]Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China.广东省人民医院[3]Department of Pharmacology, School of Pharmaceutical Sciences, Hunan University of Chinese Medicine, Changsha, China.[4]Guangdong ACXEL Micro & Nano Tech Co., Ltd, Foshan, China.[5]Medical College of South China University of Technology, Guangzhou, China.
National Natural Science
Foundation of China (Grant No. 81972792), the Natural Science
Foundation of Guangdong Province, People’s Republic of China
(Grant No. 2020A1515010149), the National key Clinical Specialty
Construction Project (2021-2024, No. 2022YW030009).
第一作者机构:[1]Department of General Surgery, Sun Yat-Sen Memorial Hospital, Guangzhou, China.[2]Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Cai D Q,Cai Diankui,Zou Yiping,et al.Construction and validation of chemoresistance-associated tumor- infiltrating exhausted-like CD8+ T cell signature in breast cancer: cr-TILCD8TSig[J].FRONTIERS IN IMMUNOLOGY.2023,14:doi:10.3389/fimmu.2023.1120886.
APA:
Cai D Q,Cai Diankui,Zou Yiping,Chen Xumeng,Jian Zhixiang...&Chen Jueming.(2023).Construction and validation of chemoresistance-associated tumor- infiltrating exhausted-like CD8+ T cell signature in breast cancer: cr-TILCD8TSig.FRONTIERS IN IMMUNOLOGY,14,
MLA:
Cai D Q,et al."Construction and validation of chemoresistance-associated tumor- infiltrating exhausted-like CD8+ T cell signature in breast cancer: cr-TILCD8TSig".FRONTIERS IN IMMUNOLOGY 14.(2023)